Intrinsiqq
Replimune Group Inc. logo

Replimune Group Inc. Dividend Analysis

REPL

Compare
Dividend0
No active dividend

This company has no dividend history.

Based on TTM and annual data · Not a buy/sell signal

This company does not pay dividends

No dividend history found in SEC filings.

Does Replimune Group (REPL) pay a dividend?

Replimune Group (REPL) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.

Frequently asked

Does Replimune Group (REPL) pay a dividend?+

No. Replimune Group (REPL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

How does Replimune Group return cash to shareholders?+

It largely does not. Replimune Group pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Could Replimune Group afford to pay a dividend?+

Not currently. Replimune Group's free cash flow is negative at -$246 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.

Which healthcare companies do pay dividends?+

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Replimune Group.

SourceDividend analysis computed from the 10-Q filed 23 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.

Fiscal year ends Mar. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL

CompareIntrinsic value
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
SRZNSurrozen, Inc.
$28.46-7.21%10
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
DNAGinkgo Bioworks Holdings Inc.
$7.46-9.02%15
IMAImageneBio, Inc.
$3.92-1.51%10
EDITEditas Medicine Inc.
$1.64-4.09%40
CMPXCompass Therapeutics Inc.
$0.69+1.40%10
IBRXImmunityBio, Inc.
$6.02-8.37%30

Held by ETFs

REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:

Spot a number that looks wrong? Check it in REPL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing REPL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.